Search the Newsreel

Mustang Bio Q2 net loss widens 41% to $1.07 million

Mustang Bio reported a Q2 net loss of $1.07 million, a 41% increase, with operating loss widening 32% to $1.17 million. Research and development expenses more than doubled, and general and administrative costs rose 20%. The company ended the quarter with $15.2 million in …

Mustang Bio, Inc. (NASDAQ: MBIO) posts $2.0M loss and faces Nasdaq bid-price warning

Mustang Bio, Inc. (NASDAQ: MBIO) reported a net loss of $2.0 million for the first six months of 2026, with an accumulated deficit of $400.7 million, and faces a Nasdaq bid-price warning. The clinical-stage oncology company, which is developing CAR T and oncolytic virus …

Mustang Bio Inc (MBIO) Financial Health: Profitability & Balance Sheet Analysis

Mustang Bio Inc (MBIO) has a current financial score of 7.56, placing it 100th out of 384 companies in the Biotechnology & Medical Research industry. The company's financial status is described as robust, although its operating efficiency is low. The article notes that relevant …

Mustang Bio Inc (MBIO) Valuation: PE, PB & Fair Value Analysis

Mustang Bio Inc (MBIO) has a current valuation score of 7.93, placing it 166th out of 385 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -1.32, which is significantly below its recent high and above its recent low. …

Mustang Bio Inc (MBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of dividend and stock split history for Mustang Bio Inc (MBIO). It states that no dividends have been distributed in the past five years. The article also lists several stock merger events with varying ratios, primarily in January 2025 …

Mustang Bio Inc (MBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown for Mustang Bio Inc (MBIO), noting that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It provides current stock information for MBIO, including its price, change, and market …

Mustang Bio Inc (MBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Mustang Bio Inc (MBIO), focusing on its support and resistance levels, and insights from various technical indicators and moving averages. As of the analysis, MBIO's stock price is trading between a resistance level of 0.68 and a …

Mustang Bio Inc (MBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Mustang Bio Inc (MBIO), listing major shareholders and their respective proportions, such as Fortress Biotech Inc and Kestra Advisory Services, LLC. It also categorizes shareholders by type (e.g., Investment Advisor, Corporation, Hedge Fund) and provides a historical …

Mustang Bio Inc (MBIO) Institutional Confidence

This article from TradingKey provides an overview of the institutional confidence in Mustang Bio Inc. (MBIO), showing a current score of 3.00, unchanged from the previous score. It details the institutional shareholdings of major firms like Fortress Biotech Inc., Kestra Advisory Services, LLC, and …

TradingKey

This article provides a detailed quarterly and annual balance sheet for Mustang Bio Inc (MBIO), allowing users to evaluate the company's financial health, analyze fundamentals, and calculate key liquidity and leverage ratios. It highlights specific financial metrics like cash and short-term investments, total assets, …

MBIO|Mustang Bio Inc|Price:0.562|Chg%:-0.008

This article provides a comprehensive stock analysis of Mustang Bio Inc (MBIO) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. Despite a high growth potential and relatively healthy fundamentals, the stock is trending downwards …

MUSTANG BIO, INC. Shares Outstanding (MBIO)

This article provides a snapshot of MUSTANG BIO, INC.'s (MBIO) shares outstanding, showing annual and quarterly diluted weighted-average share counts. In FY2025, the diluted shares outstanding were 4.9M, increasing to 6.7M in Q1 FY26. The data is derived from SEC EDGAR filings and is …

MBIO Q4 2024 Earnings: Massive EPS Miss Highlights Ongoing Challenges for Clinical-Stage Biotech - EPS Consistency Score

Mustang Bio stock trades lower as cash runway and trial update shape outlook

Mustang Bio's stock is trading lower due to a limited cash runway, ongoing clinical trials for rare cancers and gene therapy, and the search for strategic options. The company reported $0 revenue in Q1 2026 but narrowed its net loss to $7.8 million, with …

Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Stage - Post-Earnings Reaction

Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Massive EPS Miss Amidst No Revenue - Cash Flow Report

MUSTANG BIO, INC. 1Q 2026: Net loss $(955)K, EPS $(0.14) — 10-Q Summary

Mustang Bio (MBIO) Earnings Date and Reports 2026